Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Corbus Pharmaceuticals Holdings, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, with CEO Yuval Cohen presenting and attending investor meetings [1][2] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3]